Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.12 +0.48 (+1.14%)
Streaming Delayed Price Updated: 10:09 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
News headline image
The Latest Analyst Ratings for Exelixis ↗
 
Via Benzinga
News headline image
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗
 
Via Benzinga
News headline image
US Stocks Look To Snap String Of Weekly Losses As Futures Signal Positive Start Ahead Of Service Sector Data, Fed Speeches ↗
U.S. stocks have returned to their cautious ways after their resilience performance on Thursday. The major index futures point to a modestly higher opening on Friday. Cues From Thursday’s Trading: 
Via Benzinga
News headline image
Dell, Zscaler, Marvell Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Looking Into Exelixis's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
News headline image
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip ↗
A 33% plunge in the growth-dependent Nasdaq Composite is the perfect excuse for investors to buy into these innovative businesses. 
Via The Motley Fool
News headline image
Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer ↗
 
Via Benzinga
News headline image
2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗
These stocks may soon start turning heads with their revenue growth. 
Via The Motley Fool
News headline image
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb and Exelixis, Inc.
Via Business Wire
News headline image
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These companies could grow in prominence in the coming years. 
Via The Motley Fool
News headline image
Exelixis (EXEL) Q4 2022 Earnings Call Transcript ↗
EXEL earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Earnings Outlook For Exelixis ↗
 
Via Benzinga
6 Analysts Have This to Say About Exelixis ↗
 
Via Benzinga
News headline image
Is Exelixis Stock a Buy Now? ↗
Don't be too quick to dismiss this company as a one-trick pony. 
Via The Motley Fool
News headline image
3 No-Brainer Stocks to Buy Right Now for Less Than $25 ↗
All three healthcare stocks are showing solid long-term potential. 
Via The Motley Fool
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
From Exelixis, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023 ↗
 
Via Benzinga
News headline image
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue ↗
 
Via Benzinga
News headline image
Exelixis Announces Update on Patent Litigation with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
News headline image
7 Biotech Stocks That Will Make You Rich in 10 Years ↗
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
From Exelixis, Inc.
Via Business Wire
News headline image
Four Undervalued Healthcare Stocks for 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. 
Via MarketBeat
News headline image
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
From Exelixis, Inc.
Via Business Wire
News headline image
2 Top Biotech Stocks to Buy for the Long Haul ↗
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
News headline image
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
From Exelixis, Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.